Traditional EPI vaccines are considered to be among the most efficient uses of scarce
health care resources. Today, there are many under-used and new vaccines available.
In the short- to medium-term, these vaccines will not cost the few cents per dose
the traditional vaccines do, but will be 'multi-dollar' vaccines. Decision-makers
will need information, among other things, on their relative cost-effectiveness. A
number of reviews have indicated that there is scope for improving the transparency,
completeness and comparability of economic evaluations of vaccination programmes.
Thus, there is a need to improve the quality of economic evaluations of vaccination
programmes. Adherence to general guidelines would increase the quality, interpretability
and transferability of future analyses. However, there is reason to believe that there
might also be a need for more specific advice for vaccination programmes. For example,
there are inconsistencies in the methods used to estimate the future benefits of vaccination
programmes and the relative efficiency of these programmes can be sensitive to some
of the more controversial aspects of general guidelines, such as the inclusion of
indirect costs and the discounting of health outcomes. This guide has been developed
in order to meet the needs of decision-makers for relevant, reliable and consistent
economic information. They aim to provide clear and concise, practical and high quality
guidance for those who conduct economic evaluations.
Copyright 2009 Elsevier Ltd. All rights reserved.